LEGN Stock Summary and Trading Ideas (Legend Biotech - American Depositary Shares | NASDAQ:LEGN)

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

Legend Biotech - American Depositary Shares trades on the NASDAQ stock market under the symbol LEGN.

As of December 18, 2025, LEGN stock price declined to $21.28 with 1,632,118 million shares trading.

LEGN has a beta of 0.46, meaning it tends to be less sensitive to market movements. LEGN has a correlation of 0.02 to the broad based SPY ETF.

LEGN has a market cap of $3.90 billion. This is considered a Mid Cap stock.

Last quarter Legend Biotech - American Depositary Shares reported $272 million in Revenue and -$.05 earnings per share. This fell short of revenue expectation by $-4 million and exceeded earnings estimates by $.07.

In the last 3 years, LEGN traded as high as $77.32 and as low as $21.19.

The top ETF exchange traded funds that LEGN belongs to (by Net Assets): IBB, IEMG, MCHI, EEM, IXUS.

LEGN has underperformed the market in the last year with a price return of -38.6% while the SPY ETF gained +13.1%. LEGN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -38.3% and -23.3%, respectively, while the SPY returned +2.9% and -1.1%, respectively.

LEGN support price is $20.60 and resistance is $22.24 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LEGN shares will trade within this expected range on the day.